Embryonic germ cell extracts erase imprinted genes and improve the efficiency of induced pluripotent stem cells

Scientific Reports
Jing HuLei Lei

Abstract

Patient-specific induced pluripotent stem cells (iPSCs) have the potential to be useful in the treatment of human diseases. While prior studies have reported multiple methods to generate iPSCs, DNA methylation continues to limit the totipotency and reprogramming efficiency of iPSCs. Here, we first show the competency of embryonic germ cells (EGCs) as a reprogramming catalyst capable of effectively promoting reprogramming induced by four defined factors, including Oct4, Sox2, Klf4 and c-Myc. Combining EGC extracts with these four factors resulted in formation of more embryonic stem cell-like colonies than did factors alone. Notably, expression of imprinted genes was higher with combined induction than with factors alone. Moreover, iPSCs derived from the combined inductors tended to have more global hypomethylation. Our research not only provides evidence that EGC extracts could activate DNA demethylation and reprogram imprinted genes, but also establishes a new way to enhance reprogramming of iPSCs, which remains a critical safety concern for potential use of iPSCs in regenerative medicine.

References

Sep 3, 2002·Mechanisms of Development·Petra HajkovaM Azim Surani
Feb 23, 2007·Molecular Biology of the Cell·Christel T FrebergPhilippe Collas
Jul 16, 2008·American Journal of Medical Genetics. Part a·Bernhard Horsthemke, Joseph Wagstaff
Dec 26, 2008·Molecular Biology Reports·Shujian ChangJicheng Yang
Aug 1, 2009·The Anatomical Record : Advances in Integrative Anatomy and Evolutionary Biology·Yan-Ning XuLei Lei
May 28, 2010·Stem Cell Research & Therapy·Ugljesa Djuric, James Ellis
Sep 3, 2010·Trends in Cell Biology·Daniel D De CarvalhoPeter A Jones
Jan 5, 2011·Current Biology : CB·Thorold W TheunissenJosé C R Silva
Feb 16, 2011·Cell Research·Bernadett Papp, Kathrin Plath
Mar 12, 2011·Regenerative Medicine·Jinnuo Han, Kuldip Sidhu
Jun 4, 2011·PLoS Genetics·Koichiro NishinoAkihiro Umezawa
Jul 6, 2011·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Keisuke Okita, Shinya Yamanaka
Oct 25, 2011·International Review of Cell and Molecular Biology·Oleg L SerovAnna A Khabarova
Nov 21, 2012·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Akira WatanabeShinya Yamanaka
Apr 2, 2013·Molecular Cell·Gabriella Ficz, Wolf Reik
Oct 19, 2013·Epigenetics : Official Journal of the DNA Methylation Society·Sachiko TakikawaXiajun Li
Nov 21, 2013·Angewandte Chemie·Shinya Yamanaka
Apr 17, 2014·Genes & Development·Daniel M MesserschmidtDavor Solter
Dec 3, 2014·Advanced Drug Delivery Reviews·Iñigo de Miguel-Beriain
Mar 5, 2015·The Journal of Reproduction and Development·Jin-Gu NoDong-Hoon Kim
Oct 31, 2015·Reproduction : the Official Journal of the Society for the Study of Fertility·Bingteng XieZhonghua Liu
Feb 26, 2016·Oncoscience·Salvador Fernández-ArroyoJavier A Menendez

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
FACS
PCR
immunoprecipitation

Software Mentioned

Bioconductor
MeDIP
GO stats

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.